Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has introduced the “Sanyou Innovative Intelligent Antibody Design oneClick+ Platform,” an artificial intelligence-powered platform designed to expedite antibody development. The platform incorporates a vast database of antibody structures, enabling researchers to efficiently design and analyze potential antibody candidates.
 
OneClick+ offers a comprehensive suite of tools for creating various antibody formats, including IgG-like antibodies, nanobodies, and single-chain variable fragments. Users can input complete or partial antibody sequences and leverage the platform’s capabilities to generate detailed reports on physicochemical properties, potential mutations, and structural visualizations.
 
By automating many of the time-consuming tasks associated with antibody design, Sanyou aims to streamline the drug development process for its clients. The company believes that oneClick+ will be a valuable asset for researchers seeking to accelerate the creation of novel therapeutics.
 
“The launch of the ‘oneClick+’ platform marks a significant step forward for Sanyou Bio in the field of intelligent antibody design,” said Dr. Guojun Lang, CEO of Sanyou Bio. “The convenience it offers will completely revolutionize the way users approach antibody design. We believe that the launch of the ‘oneClick+’ platform will provide our customers with an unprecedented experience and contribute to the intelligent development of the biopharmaceutical industry.”